An Assessment of Different Filter Systems for Extracorporeal Elimination of Bivalirudin: An In Vitro Study
- 1 May 2003
- journal article
- research article
- Published by Wolters Kluwer Health in Anesthesia & Analgesia
- Vol. 96 (5), 1316-1319
- https://doi.org/10.1213/01.ane.0000057605.61063.55
Abstract
Bivalirudin is a new, direct thrombin inhibitor. We investigated the extracorporeal elimination rate of different hemofilters and one plasmapheresis filter for bivalirudin. Our data show that bivalirudin can be effectively eliminated via hemofiltration and plasmapheresis, although there were significant differences in the elimination rates among the filter systems investigated.Keywords
This publication has 5 references indexed in Scilit:
- Bivalirudin Monitored with the Ecarin Clotting Time for Anticoagulation During Cardiopulmonary BypassAnesthesia & Analgesia, 2003
- Bivalirudin pharmacokinetics and pharmacodynamics: Effect of renal function, dose, and genderClinical Pharmacology & Therapeutics, 2002
- Bivalirudin: an anticoagulant for acute coronary syndromes and coronary interventionsExpert Opinion on Pharmacotherapy, 2002
- Bivalirudin, a bivalent, thrombin specific anticoagulant as an alternative to heparin in interventional proceduresHamostaseologie, 2002
- Recombinant hirudin as an alternative for anticoagulation during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II: A 1-year experience in 57 patientsJournal of Cardiothoracic and Vascular Anesthesia, 2000